According to a recent LinkedIn post from Vetigenics, the company plans to attend the 2026 VCS/VSSO Collaborative Conference, where its team aims to engage with veterinary oncologists, researchers, and other animal health professionals. The post indicates that discussions will focus on advancements in immunotherapies and precision medicine for companion animals.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights its fully canine antibody therapies as a core topic of engagement at the event, positioning these assets within the broader veterinary oncology and animal health ecosystem. For investors, this presence suggests an emphasis on scientific networking and potential partnership development, which could support future clinical validation, adoption, and commercial pathways if interest from specialists and collaborators materializes.